Pipeline ++ Our Pipeline

We are advancing a pipeline of protein degraders, all discovered through our PRODEGY platform and with first-in-class potential.

Modalities
Programs (Targets)
Discovery
Lead Optimization
IND Enabling
Phase 1
Ownership
Bifunctional Degraders
BTX-9341 (CDK4/6)
HR+/HER2- Breast Cancer Resistant to CDK4/6i

We are developing first-in-class degraders of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), important targets for a range of cancers and clinically validated in the context of certain breast cancers. In preclinical breast cancer models, our lead candidates demonstrated superiority to CDK4/6 inhibitors through potent and highly selective degradation of CDK4 and CDK6, robust inhibition of phosphorylated Rb, cell cycle arrest and ultimately superior in vivo efficacy in breast cancer xenografts. Beyond this increased efficacy potential, we believe our degraders of CDK4 and CDK6 are differentiated to CDK4/6 inhibitor approaches through the ability to overcome key resistance mechanisms that limit the impact of inhibitors (~20% of patients have intrinsic resistance and up to 70% have acquired resistance to CDK4/6 inhibitors) and through significantly enhanced penetration of the blood-brain-barrier. We anticipate commencing clinical trials in 2024.

Ownership Logo - 1742
SOS1
KRAS Mutant Cancers

We are developing degraders of Son of Sevenless 1 (SOS1), an important upstream target in the Kirsten rat sarcoma virus (KRAS) pathway. We are also in early stages of discovery in developing degraders directly targeting KRAS. KRAS is the most frequently mutated cancer-causing oncogene and is mutated in over 20% of all human cancers, including an estimated 90% of pancreatic tumors, 45% of colorectal tumors, and 30% of lung tumors. In preclinical models, we have demonstrated that our lead candidates rapidly and potently degraded SOS1 by up to 90% with inhibition of pan-KRAS mutant cancer cell lines.

Ownership Logo - 1533
PDE4
Inflammatory Diseases e.g., HS, AD

We are exploring collaboration opportunities for our first-in-class degraders of Phosphodiesterase 4 (PDE4), a highly validated target for auto-immune and inflammatory diseases. Our PDE4 degraders are highly selective picomolar degraders of the PDE4D isoform that have shown up to 4,000-fold superior potency compared to PDE4 and JAK1/JAK2 inhibitors in inhibition of key inflammatory cytokines such as TNF-α, IFN-γ and IL-1β in preclinical models. We also believe the design of our PDE4 degraders has the potential to avoid several of the key gastrointestinal tolerability issues experienced by patients taking PDE4 inhibitors, enabling an overall favorable tolerability profile relative to other oral agents used for inflammatory diseases.

Ownership Logo - 1535
Bifunctional Degraders & Molecular Glues
2 Undisclosed Targets
Various

We are leveraging our PRODEGY platform to develop bifunctional degraders and molecular glues to pursue targets that may benefit from degradation.

Ownership Logo - 1845
Molecular Glues
Undisclosed Oncology Target(s)
Various

Biotheryx has entered into a research collaboration and license agreement with Incyte to discover and develop molecular glue degraders for multiple historically undruggable novel oncology targets.

Ownership Logo - 1531
Programs (Targets): BTX-9341 (CDK4/6)
Modalities: Bifunctional Degraders
HR+/HER2- Breast Cancer Resistant to CDK4/6i
Phase 1

We are developing first-in-class degraders of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), important targets for a range of cancers and clinically validated in the context of certain breast cancers. In preclinical breast cancer models, our lead candidates demonstrated superiority to CDK4/6 inhibitors through potent and highly selective degradation of CDK4 and CDK6, robust inhibition of phosphorylated Rb, cell cycle arrest and ultimately superior in vivo efficacy in breast cancer xenografts. Beyond this increased efficacy potential, we believe our degraders of CDK4 and CDK6 are differentiated to CDK4/6 inhibitor approaches through the ability to overcome key resistance mechanisms that limit the impact of inhibitors (~20% of patients have intrinsic resistance and up to 70% have acquired resistance to CDK4/6 inhibitors) and through significantly enhanced penetration of the blood-brain-barrier. We anticipate commencing clinical trials in 2024.

Commercial Rights:
Commercial Rights - 1742
Programs (Targets): SOS1
Modalities: Bifunctional Degraders
KRAS Mutant Cancers
Lead Optimization

We are developing degraders of Son of Sevenless 1 (SOS1), an important upstream target in the Kirsten rat sarcoma virus (KRAS) pathway. We are also in early stages of discovery in developing degraders directly targeting KRAS. KRAS is the most frequently mutated cancer-causing oncogene and is mutated in over 20% of all human cancers, including an estimated 90% of pancreatic tumors, 45% of colorectal tumors, and 30% of lung tumors. In preclinical models, we have demonstrated that our lead candidates rapidly and potently degraded SOS1 by up to 90% with inhibition of pan-KRAS mutant cancer cell lines.

Commercial Rights:
Commercial Rights - 1533
Programs (Targets): PDE4
Modalities: Bifunctional Degraders
Inflammatory Diseases e.g., HS, AD
Lead Optimization

We are exploring collaboration opportunities for our first-in-class degraders of Phosphodiesterase 4 (PDE4), a highly validated target for auto-immune and inflammatory diseases. Our PDE4 degraders are highly selective picomolar degraders of the PDE4D isoform that have shown up to 4,000-fold superior potency compared to PDE4 and JAK1/JAK2 inhibitors in inhibition of key inflammatory cytokines such as TNF-α, IFN-γ and IL-1β in preclinical models. We also believe the design of our PDE4 degraders has the potential to avoid several of the key gastrointestinal tolerability issues experienced by patients taking PDE4 inhibitors, enabling an overall favorable tolerability profile relative to other oral agents used for inflammatory diseases.

Commercial Rights:
Commercial Rights - 1535
Programs (Targets): 2 Undisclosed Targets
Modalities: Bifunctional Degraders & Molecular Glues
Various
Discovery

We are leveraging our PRODEGY platform to develop bifunctional degraders and molecular glues to pursue targets that may benefit from degradation.

Commercial Rights:
Commercial Rights - 1845
Programs (Targets): Undisclosed Oncology Target(s)
Modalities: Molecular Glues
Various
Discovery

Biotheryx has entered into a research collaboration and license agreement with Incyte to discover and develop molecular glue degraders for multiple historically undruggable novel oncology targets.

Commercial Rights:
Commercial Rights - 1531
background image

Pipeline ++ Partner With Us

Our Business Development team works hand in hand with our Research and Development team to thoughtfully identify prospective external opportunities that are aligned with Biotheryx’s mission and pipeline. We also actively seek discovery, development and commercialization partners, with the goal of accelerating the advancement of our novel targeted protein degraders.

Biotheryx collaborates with leading academic institutions and biopharmaceutical companies to enhance our discovery and development efforts. If you have a proposal or interest in a partnership, please contact us at [email protected].

Incyte Collaboration

In April 2023, Biotheryx entered into a research collaboration and license agreement with Incyte to discover and develop targeted protein degraders for multiple historically undruggable novel oncology targets.

Biotheryx will leverage its distinctive Cereblon-based PRODEGY platform to discover and design degraders with an initial focus on molecular glue degraders. Read the announcement press release to learn more.